Remodulin and Tracheitis - a phase IV clinical study of FDA data

Summary:

We study 52,540 people who have side effects when taking Remodulin. Tracheitis is found, especially among people who are male, 0-1 old, also take Tracleer and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people take Remodulin and have Tracheitis. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

What are phase IV trials?

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 24, 2023

52,540 people reported to have side effects when taking Remodulin.
Among them, 19 people (0.04%) have Tracheitis.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is used in primary pulmonary hypertension. Currently, eHealthMe is studying from 52,567 Remodulin users.

What is Tracheitis?

Tracheitis (an inflammation of the trachea) is found to be associated with 714 drugs and 433 conditions by eHealthMe. Currently, we are studying 1,340 people who have Tracheitis.

Number of Remodulin and Tracheitis reports submitted per year:

Gender of people who have Tracheitis when taking Remodulin *:

female: 35.29 %
male: 64.71 %

Age of people who have Tracheitis when taking Remodulin *:

Common drugs people take besides Remodulin *:

Common side effects people have besides Tracheitis *:

Pneumonia: 4 people, 21.05%
Respiratory Distress (difficulty in breathing): 3 people, 15.79%
Breathing Difficulty: 3 people, 15.79%
Fever: 3 people, 15.79%
White Blood Cell Count Increased: 2 people, 10.53%
Bronchopulmonary Dysplasia (chronic lung disorder in infants - enlargement of an organ or tissue by the proliferation of cells of an abnormal type): 2 people, 10.53%
Acute Respiratory Failure: 2 people, 10.53%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 5.26%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 5.26%
Hepatocellular Carcinoma (liver cancer): 1 person, 5.26%

Common conditions people have *:

Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 5.26%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and have Tracheitis?

Check whether Tracheitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Tracheitis and when was it recovered:

Tracheitis in Remodulin

Expand to all the drugs that have ingredients of treprostinil sodium:

Tracheitis and drugs with ingredients of treprostinil sodium

Alternative drugs to, pros and cons of Remodulin:

Remodulin (52,567 reports)

Browse all side effects of Remodulin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Tracheitis treatments and more:

Tracheitis (1,340 reports)

All the drugs that are associated with Tracheitis:

Tracheitis (714 drugs)

All the conditions that are associated with Tracheitis:

Tracheitis (433 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Remodulin) and Remodulin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.